Biomarker Discovery in Lung Cancer - Malaysia
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to 1. Identify biomarkers and signatures to differentiate between high-risk and lung cancer patients. 2. Discover blood-based biomarkers that can be used as an adjunct test to imaging diagnosis to improve patient follow-up.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Healthy Volunteers: t
View:
• Male or female subjects aged 30 and above.
• No previous history of any cancers.
• Able to provide X-ray and/or LDCT results.
• Have either COPD or pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician
• Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care.
• Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit).
Locations
Other Locations
Malaysia
University of Malaya Medical Centre
RECRUITING
Kuala Lumpur
Contact Information
Primary
Mau Ern Poh
ernestpoh@gmail.com
+60379494422
Time Frame
Start Date: 2024-01-16
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 400
Treatments
A - High risk cohort
i. Male or female subjects aged 30 and above. ii. No previous history of any cancers. iii. Able to provide X-ray and/or LDCT results. iv. Have one of the following conditions:~1. COPD~2. Pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician~v. Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care.~vi. Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit).
B - Highly suspicious of lung cancer
i. Male or female subjects aged 30 and above. ii. No previous history of any cancers. iii. Able to provide X-ray and/or LDCT results. iv. Have one of the following conditions:~1. Suspicious nodules measuring more than 11mm.~2. Imaging diagnosis suggestive of lung cancer.~v. Willing to enrol for biopsy for confirmation. vi. Willing to provide up to 39mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit).
Related Therapeutic Areas
Sponsors
Collaborators: MiRXES Pte Ltd
Leads: University of Malaya